Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07718100
NA

Effect of Systemic Ozone Therapy on Corneal Endothelium

Sponsor: Yuzuncu Yil University

View on ClinicalTrials.gov

Summary

This study evaluates the safety of systemic ozone therapy on the corneal endothelium, a vital non-renewable tissue that maintains corneal transparency. Ozone therapy is increasingly used for chronic pain, osteoarthritis, fibromyalgia, and other conditions due to its immune-modulating and antioxidant effects. However, its impact on the corneal endothelium has not been thoroughly investigated. This prospective controlled cohort study includes 96 participants: 48 patients receiving systemic ozone therapy (major autohemotherapy, 40 µg/mL, 10 sessions) and 48 age- and sex-matched healthy controls. Corneal endothelial parameters including endothelial cell density (ECD), hexagonality (Hex%), coefficient of variation (CV), central corneal thickness (CCT), and intraocular pressure (IOP) are measured by specular microscopy at baseline (T0), 1 month (T1), 3 months (T2), and 6 months (T3). Oxidative stress markers (MDA, SOD, GSH-Px) are also assessed in the ozone group. The primary goal is to determine whether systemic ozone therapy causes any adverse effects on corneal endothelial cells over a 6-month period. Secondary goals include evaluating changes in oxidative stress markers and assessing the correlation between systemic antioxidant effects and corneal health. Results will help guide clinical practice regarding the safety of ozone therapy in patients with or without pre-existing corneal conditions.

Official title: Effect of Systemic Ozone Therapy on Corneal Endothelium: A Prospective Controlled Cohort Study With Specular Microscopy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

96

Start Date

2026-01-14

Completion Date

2026-07-14

Last Updated

2026-07-21

Healthy Volunteers

Yes

Interventions

OTHER

Systemic Ozone Therapy

Major autohemotherapy (MAH) using a medical-grade ozone generator (Ozonosan Alpha Plus, Herrmann Apparatebau GmbH, Germany). Approximately 100 mL of the patient's blood is drawn into a sterile glass bottle containing 3.8% sodium citrate as an anticoagulant. The blood is then exposed to an ozone-oxygen mixture at a concentration of 40 µg/mL. The ozonated blood is gently mixed and reinfused intravenously over 10-15 minutes. The procedure is performed once daily for 10 consecutive sessions.

Locations (1)

Yuzuncu Yil University

Van, Turkey (Türkiye)